Display Settings:

Items per page

Results: 6

1.

Figure 5. From: The src phosphorylation of its epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.

Representative images from phospho-Trask immunostains are shown for a number of subtypes of epithelial cancers as indicated.

Ching Hang Wong, et al. Clin Cancer Res. ;15(7):2311-2322.
2.
Figure 4

Figure 4. From: The src phosphorylation of its epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.

A) Representative images from immunostains of colon tubular adenomas is shown. In contrast to normal colonic crypts, where Trask phosphorylation is restricted to mitotic cells, in adenomas there is abundant Trask phosphorylation in many clusters and foci of tumor cells. There is also abundant tumor cell luminal shedding. B) The frequent luminal shedding in adnomas is non-mitotic as confirmed by the absence of phospho-Histone H3 staining.

Ching Hang Wong, et al. Clin Cancer Res. ;15(7):2311-2322.
3.
Figure 1

Figure 1. From: The src phosphorylation of its epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.

The expression and phosphorylation of Trask were determined and compared in a diverse panel of epithelial cancer cell lines. Total cell lysates were immunoprecipitated with rabbit anti-Trask antibodies and immunoblotted with mouse anti-Trask antibodies or anti-phosphotyrosine antibodies. The MDA-231 cell lysate was included in all blots as a basis to allow comparison of Trask expression and phosphorylation across different blots. The MCF10A cell lysate is also included at the far right as an example of untransformed epithelial cells. Arrows indicate the 140kd and 85kd forms of Trask.

Ching Hang Wong, et al. Clin Cancer Res. ;15(7):2311-2322.
4.
Figure 3

Figure 3. From: The src phosphorylation of its epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.

A) Sections from normal colon biopsies were prepared and stained with anti-phospho-Trask antibodies. The staining intensity was scored by two observers according to procedures and definitions described in methods. All immunostains and their analyses were conducted using well defined positive and negative controls as described in methods. Trask phosphorylation is seen in occasional mitotic cells. This is shown here in the mitotically active crypt regions of normal colonic mucosa. The detaching cells in the crypts were confirmed to be epithelial cells and not extrinsic cells as shown by staining with the intestinal epithelial differentiation marker CDX2 and confirmed to be mitotic cells by the mitotic marker phospho-histone H3. B) Trask phosphorylation is also seen in some clusters of cells at the apices of colonic villi where shedding commonly occurs.

Ching Hang Wong, et al. Clin Cancer Res. ;15(7):2311-2322.
5.
Figure 2

Figure 2. From: The src phosphorylation of its epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.

A) The HCT116 and DLD-1 (colon cancer), MiaPaCa2 (pancreatic cancer), and PC3 (prostate cancer) epithelial cancer cells were harvested either while adherent (labelled A) or 2 hours after being forced into suspension by EDTA (labelled S). Cell lysates were analyzed for the expression and phosphorylation of Trask as indicated. Arrows indicate the 140kd and 85kd forms of Trask. B) The expression and phosphorylation of Trask was determined and compared in L3.6pl-luc pancreatic cancer cells under different in vitro and in vivo circumstances. These L3.6pl-luc cells express luciferase for use in in vivo imaging. All immunoprecipitates are from equal amounts of cell lysate. Lane 1 and 2 correspond to lysates from adherent and suspended cells respectively, growing in vitro. These cells were also grown orthotopically within the pancreas of nude mice and their growth monitored by in vivo imaging as described in methods. Well established pancreatic tumors from two different sacrificed mice were harvested, snap frozen, and their lysates used in lanes 3,4. A peritoneal metastasis from one of the mice was removed and lysate used in lane 5. These data comparing the same cancer cells in vitro and in vivo show that despite the more restricted phosphorylation of Trask in the in vitro growth model, their tumorigenic growth in vivo is characterized by maximal and constitutive phosphorylation of Trask.

Ching Hang Wong, et al. Clin Cancer Res. ;15(7):2311-2322.
6.

Figure 6. From: The src phosphorylation of its epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.

A) SYF cells were transfected with a pcDNA4-MycTrask expression vector and either Src or Yes expressing vectors and the expressed Trask protein was immunoprecipitated with anti-myc antibodies and immunoblotted with anti-phosphotyrosine or anti-Trask antibodies. Lanes correspond to 1) untransfected cells, 2) cells transfected with pcDNA4-MycTrask and pCMV6 vector, 3) cells transfected with pcDNA4-MycTrask and pCMV6-src, 4) cells transfected with pcDNA4-MycTrask and pCMV6-yes. Lane 5 contains the same lysate as lane 4 but was immunoprecipitated with IgG control. B) PyMT induced mammary tumors were generated in mice as described in Methods and allowed to grow to about 2.5 cm in size. Mice were sacrificied and tumor tissues were fixed in formalin and lung metastases were dissected, identified and fixed. Sections of normal mammary tissue from control mice as well as sections from PyMT induced tumors and their lung metastases were studied by immunohistochemical analyses to determine the expression and phosphorylation of Trask. Tumors from mice treated with the Src inhibitor dasatinib for 1 week were also harvested for analysis. Trask phosphorylation is induced in this tumor model and dephosphorylated by Src inhibitor therapy. C) Mice were orthotopically implanted with PyMT induced syngeneic tumors and after tumors were established at approximately one month, 30 tumor-bearing mice were randomized to two arms and treated with dasatinib or DMSO control and tumor sizes were measured twice weekly.

Ching Hang Wong, et al. Clin Cancer Res. ;15(7):2311-2322.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk